+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Viral Vector and Plasmid Manufacturing Market: Focus on Vector Type, Application, Disease, 5 Region's Data, 15 Countries' Data, Patent Landscape and Competitive Insights - Analysis and Forecast, 2020-2030

  • ID: 5055391
  • Report
  • May 2020
  • Region: Global
  • 275 Pages
  • BIS Research
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now
Global Viral Vector and Plasmid Manufacturing Market to Reach $5.86 Billion by 2030

FEATURED COMPANIES

  • Aldevron, LLC
  • Catalent, Inc.
  • GenScript
  • Merck KGaA
  • Novasep Holding SAS
  • Sartorius AG
  • MORE

Market Report Coverage - Viral Vector and Plasmid Manufacturing

Market Segmentation

  • Vector Type - Plasmid DNA and Viral Vector
  • Viral Vector Type - Adenovirus, Adeno-Associated Virus, Retrovirus, Lentivirus, Vaccinia Virus, and Other Viral Vectors
  • Disease Type - Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, and Other Diseases
  • Application - Gene Therapy, Cell Therapy, Vaccinology, and Other Applications

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Switzerland, Belgium, Spain, and Rest-of-Europe
  • Asia-Pacific - China, Australia, Japan, India, South Korea, Singapore, and Rest-of-Asia-Pacific
  • Rest-of-the-World - Latin America and Middle-East and Africa

Growth Drivers

  • Rising Prevalence of Cancer, Genetic Disorders, and Infectious Diseases
  • Rapid Uptake of Viral and Plasmid Vectors for the Development of Innovative Therapies
  • Increasing Number of Clinical Studies for the Development of Gene Therapy
  • Favorable Funding Scenario for Vector-Based Therapies

Market Challenges

  • Unaffordable Cost of Gene Therapies
  • High Manufacturing Costs of Viral Vectors and Plasmids
  • Complications Associated with Large-Scale Production of Vectors

Market Opportunities

  • Rising Demand for Synthetic Genes
  • Emergence of Next-Generation Vectors

Key Companies Profiled

FUJIFILM Holdings Corporation, GENERAL ELECTRIC, Lonza, Merck KGaA, MolMed S.p.A., Novasep Holding, Oxford Biomedica plc, Catalent, Inc., Thermo Fisher Scientific, Inc., GenScript, Boehringer Ingelheim, Wuxi AppTec Co., Ltd., Sartorius AG, Takara Bio Inc., and Aldevron, L.L.C.

Key Questions Answered:

  • What is a vector, and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors?
  • What are the major advancements in the viral vector and plasmid manufacturing sector? What are the key trends of the global viral vector and plasmid manufacturing market? How is the market evolving and what is its future scope?
  • What are the major drivers, challenges, and opportunities of the global viral vector and plasmid manufacturing market?
  • What are the key developmental strategies implemented by the key players of the global viral vector and plasmid manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
  • What is the regulatory scenario of the global viral vector and plasmid manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral vector and plasmid manufacturing products?
  • What are the major milestones in patenting activity in the global viral vector and plasmid manufacturing market?
  • What was the market size of the global viral vector and plasmid manufacturing market in 2019, and what is the market size anticipated to be in 2030? What is the expected growth rate of the global viral vector and plasmid manufacturing market during the period between 2020 and 2030?
  • What are the global market size for manufacturing plasmids and different types of viral vectors available in the global viral vector and plasmid manufacturing market in 2019? What are the key trends of the market with respect to different vectors and which vector type is expected to dominate the market during the forecast period 2020-2030?
  • What are the different disease areas where plasmids and viral vectors are employed in the global viral vector and plasmid manufacturing market? Which disease type dominated the market in 2019 and is expected to dominate in 2030?
  • What are the different applications associated with the viral vector and plasmid manufacturing? What was the contribution of each of the application areas in the global viral vector and plasmid manufacturing market in 2019, and what is expected in 2030?
  • Which region is expected to contribute the highest sales to the global viral vector and plasmid manufacturing market during the period between 2019 and 2030? Which region and country carry the potential for significant expansion of key companies in the viral vector and plasmid manufacturing market? What are the leading countries of different regions that contribute significantly toward the growth of the market?
  • Which are the key players of the global viral vector and plasmid manufacturing market, and what are their roles in the market? What was the market share of the key players in 2019?

Market Overview

The ability of vectors to carry out genetic modification through the introduction of therapeutic DNA/gene into a patient's body or cell has enabled its application in a wide range of modern therapies, including cell and gene therapies. The growing prominence of these therapies in different medical applications has therefore resulted in an increased demand for both viral and non-viral vectors. Vector-based therapies are currently being used for the treatment of a large number of diseases, including cancer, infectious diseases, genetic diseases, and cardiovascular diseases, among others. Viral vectors and plasmids reduce the cost of treatment and help in decreasing repeated administrations of medications. Moreover, vectors are also increasingly being used in the field of vaccinology for the development of vaccines owing to the advantage offered by them in inducing a wide range of immune response types. Several players, including biopharmaceutical companies, research institutes, contract manufacturing organizations, and non-profit organizations, have therefore focussed their interest on the development and production of viral vectors and plasmids.

Our healthcare experts have found viral vector and plasmid manufacturing industry to be one of the most rapidly evolving markets, and the global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030. The market is driven by certain factors, which include the success of vector-based cell and gene therapies in treating various therapeutic conditions, an increasing number of clinical studies in the field of gene therapy and availability of funding for vector-based gene therapy development, technological advancements in the biomanufacturing sector, and growing investments for expanding vector manufacturing facilities.
 
The market is favoured by the rising prevalence of genetic disorders, cancer, and infectious diseases that have raised the demand for advanced therapeutics and increasing acceptance for comparatively newer treatment options in developing countries. However, the growth of the market is also affected by several factors. Exorbitant manufacturing cost and highly regulated processes for large-scale vector production are the key challenges cited by industry experts. In addition, lack of required infrastructure and the shortfall of expertise in terms of scale, complexities, and quality assurance for vector production are some of the factors restraining the market growth. However, the rise of contract manufacturers has effectively addressed the above-articulated manufacturing challenges by offering a wide range of vector manufacturing services that offer lucrative opportunities for the growth of the market. Further, an increase in research and developmental activities in vector engineering offers a strong promise to drive the growth of the viral vector and plasmid manufacturing market in the upcoming years.

Within the research report, the market is segmented on the basis of vector type, application, disease, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of viral vector and plasmid in various therapies on the global level has created a buzz among companies to invest significantly in viral vector and plasmid manufacturing market. The market is highly competitive, marking the presence of several contract manufacturing organizations and biopharmaceutical companies, who are engaged in in-house vector manufacturing. Among the different players of the market, Lonza and Thermo Fisher Scientific hold the majority of the market share. Other companies contributing significantly toward the growth of the global viral vector and plasmid manufacturing market include GE Healthcare, Fujifilm Holding Corporation, Merck KGaA, Oxford Biomedica plc, Sartorius AG, and Catalent, Inc., among others. On the basis of region, North America holds the largest market share, while Asia-Pacific is anticipated to grow at the fastest CAGR during the forecast period.

Enterprise License customers will receive an Excel spreadsheet containing additional data.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aldevron, LLC
  • Catalent, Inc.
  • GenScript
  • Merck KGaA
  • Novasep Holding SAS
  • Sartorius AG
  • MORE

Executive Summary

1 Product Definition

2 Scope of the Work
2.1 Overview: Report Scope
2.2 Segmentation of the Global Viral Vector and Plasmid Manufacturing Market
2.3 Assumptions and Limitations
2.4 Key Questions Answered in the Report
2.5 Base Year and Forecast Period

3 Research Methodology
3.1 Overview: Report Methodology

4 Global Viral Vector and Plasmid Manufacturing Market Overview
4.1 Market Overview
4.2 Introduction to Vectors
4.3 Importance of Viral Vectors and Plasmid DNA
4.4 Major Milestone in Vector Manufacturing
4.4.1 Manufacturing Process
4.4.1.1 Upstream Bioprocessing
4.4.1.2 Downstream Bioprocessing
4.5 Global Viral Vector and Plasmid Manufacturing Market Size, 2019-2030

5 Market Dynamics
5.1 Market Drivers
5.1.1 Rapid Uptake of Viral Vectors and Plasmid for the Development of Innovative Therapies
5.1.2 Rising Prevalence of Cancer, Genetic Disorders, and Infectious Diseases
5.1.3 Increasing Number of Clinical Studies for the Development of Gene Therapy
5.1.4 Favorable Funding Scenario for Vector-Based Therapies
5.2 Market Restraints
5.2.1 Unaffordable Cost of Gene Therapies
5.2.2 High Manufacturing Costs of Viral Vectors and Plasmids
5.2.3 Complications Associated With Large-Scale Production of Vectors
5.3 Market Opportunities
5.3.1 Rising Demand for Synthetic Genes
5.3.2 Emergence of Next-Generation Vectors

6 Industry Insights
6.1 Overview
6.2 Regulatory Scenario
6.3 Patent Landscape

7 Competitive Landscape
7.1 Overview
7.2 Key Developments and Strategies
7.2.1 Partnerships and Alliances
7.2.2 Business Expansions
7.2.3 New Offerings
7.2.4 M & A Activities
7.2.5 Others
7.3 Market Share Analysis

8 Global Viral Vector and Plasmid Manufacturing Market (by Vector)
8.1 Overview
8.2 Viral Vector
8.2.1 Adenoviral Vector
8.2.2 Retroviral Vector
8.2.3 Adeno-Associated Viral Vector
8.2.4 Lentiviral Vector
8.2.5 Vaccinia Viral Vector
8.2.6 Other Viral Vectors
8.3 Plasmid

9 Global Viral Vector and Plasmid Manufacturing Market (by Disease)
9.1 Overview
9.2 Cancer
9.3 Genetic Disease
9.4 Infectious Disease
9.5 Cardiovascular Disease
9.6 Other Diseases

10 Global Viral Vector and Plasmid Manufacturing Market (by Application)
10.1 Overview
10.2 Gene Therapy
10.3 Vaccinology
10.4 Cell Therapy
10.5 Other Applications

11 Global Viral Vector and Plasmid Manufacturing Market (by Region)
11.1 Overview
11.2 North America
11.2.1 Overview
11.2.2 U.S.
11.2.3 Canada
11.3 Europe
11.3.1 Overview
11.3.2 Germany
11.3.3 U.K.
11.3.4 France
11.3.5 Italy
11.3.6 Switzerland
11.3.7 Belgium
11.3.8 Spain
11.3.9 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 Overview
11.4.2 China
11.4.3 Australia
11.4.4 Japan
11.4.5 India
11.4.6 South Korea
11.4.7 Singapore
11.4.8 Rest-of-Asia-Pacific
11.5 Rest-of-the-World
11.5.1 Overview

12 Company Profiles
12.1 Overview
12.2 Aldevron, LLC
12.2.1 Company Overview
12.2.2 Role of Aldevron, LLC in the Global Viral Vector and Plasmid Manufacturing Market
12.2.3 SWOT Analysis
12.3 Boehringer Ingelheim
12.3.1 Company Overview
12.3.2 Role of Boehringer Ingelheim in the Global Viral Vector and Plasmid Manufacturing Market
12.3.3 SWOT Analysis
12.4 Catalent, Inc.
12.4.1 Company Overview
12.4.2 Role of Catalent, Inc. in the Global Viral Vector and Plasmid Manufacturing Market
12.4.3 Financials
12.4.4 Key Insights About Financial Health of the Company
12.4.5 SWOT Analysis
12.5 FUJIFILM Holdings Corporation
12.5.1 Company Overview
12.5.2 Role of FUJIFILM Holdings Corporation in the Global Viral Vector and Plasmid Manufacturing Market
12.5.3 Financials
12.5.4 Key Insights About Financial Health of the Company
12.5.5 SWOT Analysis
12.6 GENERAL ELECTRIC
12.6.1 Company Overview
12.6.2 Role of GENERAL ELECTRIC in the Global Viral Vector and Plasmid Manufacturing Market
12.6.3 Financials
12.6.4 Key Insights About Financial Health of the Company
12.6.5 SWOT Analysis
12.7 GenScript
12.7.1 Company Overview
12.7.2 Role of GenScript in the Global Viral Vector and Plasmid Manufacturing Market
12.7.3 Financials
12.7.4 Key Insights About Financial Health of the Company
12.7.5 SWOT Analysis
12.8 Lonza
12.8.1 Company Overview
12.8.2 Role of Lonza in the Global Viral Vector and Plasmid Manufacturing Market
12.8.3 Financials
12.8.4 Key Insights About Financial Health of the Company
12.8.5 SWOT Analysis
12.9 Merck KGaA
12.9.1 Company Overview
12.9.2 Role of Merck KGaA in the Global Viral Vector and Plasmid Market
12.9.3 Financials
12.9.4 Key Insights About Financial Health of the Company
12.9.5 SWOT Analysis
12.10 MolMed S.p.A.
12.10.1 Company Overview
12.10.2 Role of MolMed S.p.A. in the Global Viral Vector and Plasmid Manufacturing Market
12.10.3 Financials
12.10.4 SWOT Analysis
12.11 Novasep Holding SAS
12.11.1 Company Overview
12.11.2 Role of Novasep Holding SAS in the Global Viral Vector and Plasmid Manufacturing Market
12.11.3 SWOT Analysis
12.12 Oxford Biomedica plc
12.12.1 Company Overview
12.12.2 Role of Oxford Biomedica plc in the Global Viral Vector and Plasmid Manufacturing Market
12.12.3 Financials
12.12.4 Key Insights About Financial Health of the Company
12.12.5 SWOT Analysis
12.13 Sartorius AG
12.13.1 Company Overview
12.13.2 Role of Sartorius AG in the Global Viral Vector and Plasmid Manufacturing Market
12.13.3 Financials
12.13.4 Key Insights About Financial Health of the Company
12.13.5 SWOT Analysis
12.14 Takara Bio Inc.
12.14.1 Company Overview
12.14.2 Role of Takara Bio Inc. in the Global Viral Vector and Plasmid Manufacturing Market
12.14.3 Financials
12.14.4 Key Insights About Financial Health of the Company
12.14.5 SWOT Analysis
12.15 Thermo Fisher Scientific Inc.
12.15.1 Company Overview
12.15.2 Role of Thermo Fisher Scientific Inc. in the Global Viral Vector and Plasmid Manufacturing Market
12.15.3 Financials
12.15.4 Key Insights About Financial Health of the Company
12.15.5 SWOT Analysis
12.16 WuXi AppTec
12.16.1 Company Overview
12.16.2 Role of WuXi AppTec in the Global Viral Vector and Plasmid Manufacturing Market
12.16.3 Financials
12.16.4 Key Insights About Financial Health of the Company
12.16.5 SWOT Analysis: WuXi AppTec

List of Tables
Table 1: Leading Segments of the Global Viral Vector and Plasmid Manufacturing Market, 2019 and 2030
Table 4.1: Advantages and Disadvantages of Common Viral Vectors and Plasmids
Table 5.1: Gene Therapy for Different Types of Cancer
Table 5.2: Recent Approvals for Gene Therapy
Table 5.3: Companies Offering Gene Therapies and Their Cost
Table 6.1: Global Regulatory Scenario
Table 6.2: Patents Related to Viral Vectors and Plasmids  (January 2017-February 2020)
Table 8.1: Examples of Viral Vectors Used in Gene Therapy
Table 8.2: Plasmids Used in Gene Therapy Trials
Table 9.1: Examples of Ad Vectors for Cancer Gene Therapy
Table 9.2: Features of Vectors Used in Cardiovascular Therapy
Table 10.1: Examples of Clinical Trials Using Viral Vectors
Table 10.2: Advantages and Disadvantages Associated with Major Viral Vectors
Table 11.1: Examples of Key Companies with Headquarters in the U.S.

List of Figures
Figure 1: Global Viral Vector and Plasmid Manufacturing Market (by Region), 2019 and 2030
Figure 2: Key Players of the Global Viral Vector and Plasmid Manufacturing Market
Figure 3: Drivers, Challenges, and Opportunities of the Global Viral Vector and Plasmid Manufacturing Market
Figure 4: Share of Key Developments and Strategies, January 2017-February 2020
Figure 5: Global Viral Vector and Plasmid Manufacturing Market (by Vector Type), 2019 and 2030
Figure 6: Global Viral Vector and Plasmid Manufacturing Market (by Viral Vector), 2019 and 2030
Figure 7: Global Viral Vector and Plasmid Manufacturing Market (by Disease), 2019 and 2030
Figure 8: Global Viral Vector and Plasmid Manufacturing Market (by Application), 2019 and 2030
Figure 2.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation
Figure 3.1: Global Viral Vector and Plasmid Manufacturing Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Bottom-up Approach (Segment-Wise Analysis)
Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
Figure 3.7: Assumptions and Limitations
Figure 4.1: Mechanism of Action of Vectors
Figure 4.2: Evolutionary History of Vectors
Figure 4.3: Typical Production Methods of Viral Vectors and Plasmids
Figure 4.4: Global Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 5.1: Drivers, Challenges, and Opportunities of the Global Viral Vector and Plasmid Manufacturing Market
Figure 5.2: Estimated New Cancer Cases and Deaths (by Sex), U.S., 2020
Figure 6.1: Workflow Associated With Biomanufacturing
Figure 6.2: Global Viral Vector and Plasmid Manufacturing Market: Patent Analysis (by Year of Publication), June 2017-December 2019
Figure 7.1: Competitive Landscape, January 2017- March 2020
Figure 7.2: Share of Key Developments and Strategies, January 2017-February 2020
Figure 7.3: Partnerships and Alliances (by Company), January 2017-February 2020
Figure 7.4: Business Expansions (by Company), January 2017-February 2020
Figure 7.5: New Offerings (by Company), January 2017-February 2020
Figure 7.6: M&A Activities (by Company), January 2017-February 2020
Figure 7.7: Others (by Company), January 2017-February 2020
Figure 7.8: Market Share Analysis of Global Viral Vector and Plasmid Manufacturing  Market, 2019
Figure 8.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Vector)
Figure 8.2: Global Viral Vector and Plasmid Manufacturing Market (by Vector Type), 2019 and 2030
Figure 8.3: Global Viral Vector and Plasmid Manufacturing Market for Viral Vectors, 2019-2030
Figure 8.4: Global Viral Vector and Plasmid Manufacturing Market (by Viral Vector), 2019 and 2030
Figure 8.5: Global Viral Vector and Plasmid Manufacturing Market for Adenoviral Vectors, 2019-2030
Figure 8.6: Global Viral Vector and Plasmid Manufacturing Market for Retroviral Vectors, 2019-2030
Figure 8.7: Global Viral Vector and Plasmid Manufacturing Market for Adeno-Associated Viral Vectors, 2019-2030
Figure 8.8: Global Viral Vector and Plasmid Manufacturing Market for Lentiviral Vectors,  2019-2030
Figure 8.9: Global Viral Vector and Plasmid Manufacturing Market for Vaccinia Viral Vectors, 2019-2030
Figure 8.10: Global Viral Vector and Plasmid Manufacturing Market for Other Viral Vectors, 2019-2030
Figure 8.11: Global Viral Vector and Plasmid Manufacturing Market for Viral Vectors, 2019-2030
Figure 9.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation  (by Disease)
Figure 9.2: Global Viral Vector and Plasmid Manufacturing Market (by Disease), 2019 and 2030
Figure 9.3: Global Viral Vector and Plasmid Manufacturing Market for Cancer, 2019-2030
Figure 9.4: List of Monogenic Disorders for which Human Gene Transfer Trials Have Been Approved
Figure 9.5: Global Viral Vector and Plasmid Manufacturing Market for Genetic Diseases,  2019-2030
Figure 9.6: Global Viral Vector and Plasmid Manufacturing Market for Infectious Diseases, 2019-2030
Figure 9.7: Global Viral Vector and Plasmid Manufacturing Market for Infectious Diseases, 2019-2030
Figure 9.8: Global Viral Vector and Plasmid Manufacturing Market for Other Diseases,  2019-2030
Figure 10.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation  (by Application)
Figure 10.2: Global Viral Vector and Plasmid Manufacturing Market (by Application), 2019 and 2030
Figure 10.3: Global Viral Vector and Plasmid Manufacturing Market for Gene Therapy, 2019-2030
Figure 10.4: Global Viral Vector and Plasmid Manufacturing Market for Vaccinology, 2019-2030
Figure 10.5: Global Viral Vector and Plasmid Manufacturing Market for Cell Therapy, 2019-2030
Figure 10.6: Global Viral Vector and Plasmid Manufacturing Market for Cell Therapy, 2019-2030
Figure 11.1: Global Viral Vector and Plasmid Manufacturing Market (by Region), 2019 and 2030
Figure 11.2: North America: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.3: North America: Market Dynamics
Figure 11.4: North America: Viral Vector and Plasmid Manufacturing Market (by Country),  2019 and 2030
Figure 11.5: U.S.: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.6: Canada: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.7: Europe: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.8: Europe: Market Dynamics
Figure 11.9: Europe: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030
Figure 11.10: Germany: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.11: U.K.: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.12: France: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.13: Italy: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.14: Switzerland: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.15: Belgium: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.16: Spain: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.17: Rest-of-Europe: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.18: Asia-Pacific: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.19: Asia-Pacific: Market Dynamics
Figure 11.20: Asia-Pacific: Viral Vector and Plasmid Manufacturing Market (by Country),  2019 and 2030
Figure 11.21: China: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.22: Australia: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.23: Japan: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.24: India: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.25: South Korea: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.26: Singapore: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.27: Rest-of-Asia-Pacific: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.28: Rest-of-the-World: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.29: Rest-of-the-World: Viral Vector and Plasmid Manufacturing Market (Latin America and Middle-East and Africa), 2019-2030
Figure 12.1: Shares of Key Company Profiles
Figure 12.2: Aldevron, LLC: Service/Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.3: Aldevron, LLC: SWOT Analysis
Figure 12.4: Boehringer Ingelheim: Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.5: Boehringer Ingelheim: SWOT Analysis
Figure 12.6: Catalent, Inc: Service/Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.7: Catalent, Inc: Overall Financials, 2017-2019
Figure 12.8: Catalent, Inc.: Net Revenue (by Business Segment), 2017-2019
Figure 12.9: Catalent, Inc.: Net Revenue (by Region), 2017-2019
Figure 12.10: Catalent, Inc.: R&D Expense, 2017-2019
Figure 12.11: Catalent, Inc.: SWOT Analysis
Figure 12.12: FUJIFILM Holdings Corporation: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.13: FUJIFILM Holdings Corporation: Overall Financials, 2017-2019
Figure 12.14: FUJIFILM Holdings Corporation: Net Revenue (by Business Segment), 2017-2019
Figure 12.15: FUJIFILM Holdings Corporation: Healthcare and Material Solutions Revenue (by Sub-Segment), 2017-2019
Figure 12.16: FUJIFILM Holdings Corporation: R&D Expense, 2017-2019
Figure 12.17: FUJIFILM Holdings Corporation: SWOT Analysis
Figure 12.18: GE Healthcare: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.19: GENERAL ELECTRIC Company: Overall Financials, 2017-2019
Figure 12.20: GENERAL ELECTERIC: Revenue (by Business Model), 2017-2019
Figure 12.21: GENERAL ELECTRIC: Revenue (by Region), 2017-2019
Figure 12.22: GENERAL ELECTRIC: R&D Expenditure, 2017-2019
Figure 12.23: GENERAL ELECTRIC: SWOT Analysis
Figure 12.24: GenScript: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.25: GenScript: Overall Financials, 2016-2018
Figure 12.26: GenScript: R&D Expense, 2016-2018
Figure 12.27: GenScript: SWOT Analysis
Figure 12.28: Lonza: Service/Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.29: Lonza: Overall Financials, 2017-2019
Figure 12.30: Lonza: Revenue (by Segment), 2017-2019
Figure 12.31: Lonza: Revenue (by Region), 2017-2019
Figure 12.32: Lonza: R&D Expenditure (2017-2019)
Figure 12.33: Lonza: SWOT Analysis
Figure 12.35: Merck KGaA: Overall Financials, 2017-2019
Figure 12.36: Merck KGaA: Revenue (by Product and Services), 2017-2019
Figure 12.37: Merck KGaA: Revenue (by Region), 2017-2019
Figure 12.38: Merck KGaA: R&D Expenditure, 2017-2019
Figure 12.40: MolMed S.p.A.: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.41: MolMed S.p.A.: Overall Financials, 2016-2018
Figure 12.42: MolMed S.p.A.: SWOT Analysis
Figure 12.43: Novasep Holding SAS: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.44: Novasep Holding SAS: SWOT Analysis
Figure 12.45: Oxford Biomedica plc: Service/Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.46: Oxford Biomedica plc: Overall Financials, 2016-2018
Figure 12.47: Oxford Biomedica plc: Revenue (by Segment), 2016-2018
Figure 12.48: Oxford Biomedica plc: R&D Expenditure (2016-2018)
Figure 12.49: Oxford Biomedica plc: SWOT Analysis
Figure 12.50: Sartorius AG: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.51: Sartorius AG: Overall Financials, 2017-2019
Figure 12.52: Sartorius AG: Revenue (by Business Segment), 2017-2019
Figure 12.53: Sartorius AG: Revenue (by Region), 2017-2019
Figure 12.54: Sartorius AG: R&D Expenditure (2017-2019)
Figure 12.55: Sartorius AG: SWOT Analysis
Figure 12.56: Takara Bio Inc.: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.57: Takara Bio Inc.: Overall Financials, 2017-2019
Figure 12.58: Takara Bio Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.59: Takara Bio Inc.: Revenue (by Region), 2017-2019
Figure 12.60: Takara Bio Inc.: R&D Expenditure (2017-2019)
Figure 12.61: Takara Bio Inc.: SWOT Analysis
Figure 12.62: Thermo Fisher Scientific, Inc.: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.63: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019
Figure 12.64: Thermo Fisher Scientific, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.65: Thermo Fisher Scientific, Inc.: Revenue (by Region), 2017-2019
Figure 12.66: Thermo Fisher Scientific, Inc.: R&D Expenditure (2017-2019)
Figure 12.67: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 12.68: WuXi AppTec: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.69: WuXi AppTec: Overall Financials, 2016-2018
Figure 12.70: WuXi AppTec: Net Revenue (by Business Segment), 2016-2018
Figure 12.71: WuXi AppTec: Net Revenue (by Region), 2016-2018
Figure 12.72: WuXi AppTec: R&D Expense, 2016-2018
Figure 12.73: WuXi AppTec: SWOT Analysis

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Aldevron, LLC
  • Catalent, Inc.
  • GenScript
  • Merck KGaA
  • Novasep Holding SAS
  • Sartorius AG
  • MORE

According to the new market intelligence report titled “Global Viral Vector and Plasmid Manufacturing Market - Analysis and Forecast, 2020-2030”, the global viral vector and plasmid manufacturing market was valued at $1.16 billion in 2019 and is expected to be $5.86 billion in 2030. The viral vector and plasmid manufacturing market is expected to grow at a lower double-digit compound annual growth rate in the forecast period 2020-2030. The growing prominence of vector-based gene therapy products and high funding activities in research for the development of novel therapies, coupled with an increasing prevalence of diseases, such as cancer, genetic diseases, and infectious diseases, is prominently driving the growth of the global viral vector and plasmid manufacturing market.

The rising prevalence of diseases has led to an increasing demand for the development of advanced therapies and drugs to meet the needs of the growing patient population. The advent of cell and gene therapy has offered the high potential to treat diseases that are otherwise incurable by conventional treatment modalities. Both therapies encompass the use of vector, as gene delivery vehicles, for the introduction of a therapeutic gene into the target cell in order to provide a cure or remedy to disease. Extensive progress made in gene and cell therapy research since the early 1970s and 1980s has, therefore, accelerated the adoption rate of plasmids and viral vectors for their use in these modern therapies. Progress made in the field of vaccinology, involving the use of vectors, has further intensified the demand for these vectors. A large number of preclinical and clinical studies evaluating the potential of vectors in these advanced therapies have further displayed promising results. This, in turn, has attracted the attention of investors, making viral vector and plasmid manufacturing market an active area of investment as well as encouraging favorable funding activities from both the private and public sectors.

Currently, the global viral vector and plasmid manufacturing market is witnessing the entry of several contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) that are striving hard to sustain the competition with the main goal to increase the production of vectors that would be both cost-effective and of superior quality. The market is currently dominated by juggernauts, such as Lonza, Thermo Fisher Scientific Inc, Merck KGaA, GE Healthcare, Sartorius AG, and other small-medium enterprises, which offer a wide range of vector manufacturing products and services to the market. The expansion of manufacturing facilities is one of the key strategies adopted by the companies in order to strengthen their business position. Besides, collaborations, partnerships, joint ventures, and mergers, and acquisitions are also some of the common business development strategies adopted by key companies.

According to Abdul Wahid, Principal Analyst, “The field of oncology is the major contributor of revenue in the viral vector and plasmid manufacturing market. By disease, the market is largely dominated by cancer that contributed to 56.50% of the total market share in 2019. The cancer segment was valued at $652.5 million in 2019 and is anticipated to reach $2.14 billion in 2030, registering a low double-digit CAGR during the time period between 2020 and 2030. This is mainly attributed to the progress made in vector-based CAR-T cell therapies and increasing investments in the field of oncology for the development of advanced therapies. However, among the different disease types, infectious disease is expected to account for the highest CAGR during the forecast period between 2020 and 2030.”

Research Highlights:

The leading players of the global viral vector and plasmid manufacturing market predominantly prefer partnerships and alliances to sustain the market competition and strengthen their business position. Most of the collaborations are taking place between contract manufacturers and biopharmaceutical companies, whereby one is offering their vector manufacturing facility, while the other one is involved in the development of vector-based cell and gene therapy products.

Between plasmids and viral vectors, the latter led the market in 2019 with almost 80% contribution to the global revenue. The availability of a large variety of viral vectors in the market and the benefits offered by them over plasmid vectors, mainly in terms of the longer size of the therapeutic gene that it can accommodate, were responsible for their market dominance.

Among the different viral vectors, adenovirus vector dominated the market in 2019, accounting for 26.50% of the global viral vector and plasmid manufacturing market for viral vectors. This is mainly attributed to the increased adoption rate of adenovirus vectors for performing experimental studies related to the treatment of different types of cancers, such as head and neck cancer, bladder cancer, and prostate cancer.

In terms of application areas, gene therapy was the major contributor of revenue followed by the file of vaccinology. The gene therapy segment was valued at $486.54 million in 2019 and is anticipated to reach $2.17 billion in 2030.

Among the different regions, North America led the global viral vector and plasmid manufacturing market in 2019, with the U.S. being the major contributor of revenue. The presence of a large number of well-equipped vector manufacturing facilities with advanced infrastructure and strong investments in the biomanufacturing sector is significantly promoting the growth of the viral vector and plasmid manufacturing market in North America.

This market intelligence report provides a multidimensional view of the global viral vector and plasmid manufacturing market in terms of market size and growth potential. This research report aims at answering various aspects of the global viral vector and plasmid manufacturing market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities such as product launches, partnerships, and product approvals, among others. The research report provides a comprehensive analysis of the product sales, and manufacturers and trend analysis by segment and by region.

This report is a meticulous compilation of research on more than 15 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of the leading companies, market participants, and vendors. The report also profiles 15 companies including several key players, namely FUJIFILM Holdings Corporation, GENERAL ELECTRIC, Lonza, Merck KGaA, MolMed S.p.A., Novasep Holding, Oxford Biomedica plc, Catalent, Inc., Thermo Fisher Scientific, Inc., GenScript, Boehringer Ingelheim, Wuxi AppTec Co., Ltd., Sartorius AG, Takara Bio Inc., and Aldevron, L.L.C.

The answers to the following key questions can be derived from this report:

  • What is a vector, and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors?
  • What are the major advancements in the viral vector and plasmid manufacturing sector? What are the key trends of the global viral vector and plasmid manufacturing market? How is the market evolving and what is its future scope?
  • What are the major drivers, challenges, and opportunities of the global viral vector and plasmid manufacturing market?
  • What are the key developmental strategies implemented by the key players of the global viral vector and plasmid manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
  • What is the regulatory scenario of the global viral vector and plasmid manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral vector and plasmid manufacturing products?
  • What are the major milestones in patenting activity in the global viral vector and plasmid manufacturing market?
  • What was the market size of the global viral vector and plasmid manufacturing market in 2019, and what is the market size anticipated to be in 2030? What is the expected growth rate of the global viral vector and plasmid manufacturing market during the period between 2020 and 2030?
  • What are the global market size for manufacturing plasmids and different types of viral vectors available in the global viral vector and plasmid manufacturing market in 2019? What are the key trends of the market with respect to different vectors and which vector type is expected to dominate the market during the forecast period 2020-2030?
  • What are the different disease areas where plasmids and viral vectors are employed in the global viral vector and plasmid manufacturing market? Which disease type dominated the market in 2019 and is expected to dominate in 2030?
  • What are the different applications associated with the viral vector and plasmid manufacturing? What was the contribution of each of the application areas in the global viral vector and plasmid manufacturing market in 2019, and what is it expected in 2030?
  • Which region is expected to contribute the highest sales to the global viral vector and plasmid manufacturing market during the period between 2019 and 2030? Which region and country carry the potential for significant expansion of key companies in the viral vector and plasmid manufacturing market? What are the leading countries of different regions that contribute significantly toward the growth of the market?
  • Which are the key players of the global viral vector and plasmid manufacturing market, and what are their roles in the market? What was the market share of the key players in 2019?
Note: Product cover images may vary from those shown
5 of 5
  • Aldevron, LLC
  • Boehringer Ingelheim
  • Catalent, Inc.
  • FUJIFILM Holdings Corporation
  • GENERAL ELECTRIC
  • GenScript
  • Lonza
  • Merck KGaA
  • MolMed S.p.A.
  • Novasep Holding SAS
  • Oxford Biomedica plc
  • Sartorius AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec
Note: Product cover images may vary from those shown
Adroll
adroll